Tappy,
Peer review is the key that most Biotech's view as the point at which they can release full results to investors. Peer review can be publication in a technical journal as you mention, or a presentation at a technical conference where the information is under peer review. I certainly hope it occurs somewhere soon.
The thing is, even without peer review Biotech companies will share what they consider Top Line data about the trial. This isn't much more than a statement of some degree of success, without the details, but it's something that other companies do, that OWCP has not done to date.
We know the trial is blinded, but we also believe that the company expanded the trial based on the recommendations of the clinicians running it. Without giving us detailed information, which they may, or may not know, they could have told us this was happening because of the enthusiasm of the clinicians running the trial.
I certainly hope that with, or without peer review prior to the next quarterly report, the company will tell us more than they have to date, in an official way. I do not view something told to an investors as being official notification of anything, though it's probably true. It's time for them to put it in writing.
Gary
News 
Market Data 
Discover 
AI
